Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Receivables - Net (2023 - 2025)

Historic Receivables - Net for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $3.5 million.

  • Tonix Pharmaceuticals Holding's Receivables - Net fell 1325.69% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 1325.69%. This contributed to the annual value of $3.7 million for FY2024, which is 1976.03% down from last year.
  • As of Q3 2025, Tonix Pharmaceuticals Holding's Receivables - Net stood at $3.5 million, which was down 1325.69% from $2.3 million recorded in Q2 2025.
  • Over the past 5 years, Tonix Pharmaceuticals Holding's Receivables - Net peaked at $4.6 million during Q4 2023, and registered a low of $1.6 million during Q3 2023.
  • Its 3-year average for Receivables - Net is $3.3 million, with a median of $3.4 million in 2024.
  • As far as peak fluctuations go, Tonix Pharmaceuticals Holding's Receivables - Net surged by 15691.42% in 2024, and later plummeted by 3051.81% in 2025.
  • Quarter analysis of 3 years shows Tonix Pharmaceuticals Holding's Receivables - Net stood at $4.6 million in 2023, then fell by 19.76% to $3.7 million in 2024, then decreased by 5.48% to $3.5 million in 2025.
  • Its Receivables - Net stands at $3.5 million for Q3 2025, versus $2.3 million for Q2 2025 and $3.3 million for Q1 2025.